spec sheet6 rows
LY503430 was Eli Lilly's early-2000s AMPA receptor potentiator, built to test whether boosting glutamatergic signaling could protect and even rescue dopamine neurons in Parkinson's disease. In rodent models it reduced neurotoxicity from both 6-hydroxydopamine and MPTP lesions, and remarkably still helped when dosing started days after the lesion was already established; a neurotrophic effect, not just a protective one. Lilly developed a cGMP synthesis route specifically to fund first-human-dose trials, but no published clinical data ever surfaced, and the compound appears to have been quietly dropped, likely a casualty of the same epileptogenic and safety concerns that stalled Lilly's whole AMPA potentiator program. It survives today only as a pharmacology reference compound.
- Reduced dopamine neuron loss in toxin-based PD models
- Neurotrophic rescue even when dosing was delayed after injury
- Improved motor outcomes in rodent Parkinson's models
- Reference compound for AMPA receptor pharmacology
- Shares the epileptogenic risk profile flagged in related Lilly AMPA potentiators
- Unknown pharmacokinetics in humans
- LY503430 still helped dopamine neurons in rat models even when treatment started 6 to 14 days after the lesion, well past the usual neuroprotection window.
- Its synthesis was optimized under cGMP standards for a first-human-dose trial that appears to have never produced public results.
Mechanism
Selectively potentiates native and recombinant human GluA1-4 receptors at submicromolar concentrations, enhancing -induced calcium influx in cortical, hippocampal, and substantia nigra neurons.
Safetyrisks and cautions, not medical advice
Lilly scaled a manufacturing process meant to supply a first dose in humans, and then no clinical result ever appeared, which leaves the human safety profile completely blank. Everything on the record is rat and mouse pharmacology in Parkinson's models. It sits in the same biarylpropylsulfonamide series whose more agonist-like members showed seizure risk in rodents and monkeys, so the honest reading is not that it is clean but that nobody published where its margin lies.
History
Characterized by Lilly researchers in 2003 (O'Neill et al.) with a full pharmacology profile published in CNS Drug Reviews in 2005; process chemistry was scaled for first-human-dose trials but no completed clinical trial results were ever published.
Subjective profileweighing the evidence above
Some of the most convincing preclinical Parkinson's neuroprotection data in the whole ampakine literature, and it never even got a public human trial to show for it.
Resources
This entry is here for reference.
Research
- 1.LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
- 2.LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Was LY503430 ever tested in people?
Lilly built a GMP manufacturing process meant to support first-human-dose trials, but no completed human trial results were ever published, so it's unclear if it got past very early-phase testing before the project was dropped.
Why would an AMPA potentiator help Parkinson's disease?
By boosting AMPA receptor signaling, LY503430 triggered neurotrophic factor release that protected and even partly rescued dopamine neurons in animal PD models, a different strategy than dopamine-replacement drugs like levodopa.
Limitations of the evidence
- No human safety data was ever published
Adverse effects
- Shares the epileptogenic risk profile flagged in related Lilly AMPA potentiators
- Unknown pharmacokinetics in humans